Delivery Order W911SR22D0009-W911SR22F0073
- Not listed
- On March 7, 2023, the Joint PEO Chemical and Biological Defense awarded a cost-plus-fixed-fee delivery order valued at $9.08 million to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) for drug substance process validation, drug product process validation, Phase 3 clinical development, and storage/stability testing of a monoclonal antibody countermeasure against botulinum neurotoxin exposure designated BONT mAb G03-52-01. The ultimate objective is to achieve U.S....
- This is a $107,935,344.00 cost-plus-fixed-fee delivery order awarded to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) by the Joint PEO Chemical and Biological Defense, a component of the U.S. Department of the Army. The order is for tasks associated with the development of a U.S. Food and Drug Administration licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure. The work will be performed in Frederick, Maryland, and the order has a...
- The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $92 million firm fixed price definitive contract to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., for fill and finish capacity. The contract is funded through the National Interest Action Code for Coronavirus COVID-19 and will be performed in Alachua, Florida through July 2021. As the prime, Nanotherapeutics will provide pharmaceutical manufacturing...
- The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $8,363,045 Other Transaction Agreement to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., for the prototype development of a monoclonal antibody (MAB) countermeasure designated VRC114. The contract does not have a set-aside designation. Resilience Government Services is a technology-focused biomanufacturing company that has previously supported the Department...
- This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
- This is a prime contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services. The $14,898,362.53 cost-plus-fixed-fee contract is for biomedical research and development. It has a period of performance through December 31, 2011 and does not have a set-aside designation. Resilience Government Services is a technology-focused...
- This is a federal contract award from the U.S. Army Medical Command (MEDCOM) to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., a technology-focused biomanufacturing company. The $970,700.00 Cost Plus Fixed Fee contract is for research and development work related to the Telemedicine and Advanced Technology Research Center (TATRC) program. The contract has no set-aside designation and has an ultimate completion date of September 30, 2013. Resilience Government...
- This federal contract award was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $4,761,491.00 cost-plus-fixed-fee contract is a delivery order under the Fill and Finish Manufacturing Network (FFMN) Indefinite Delivery Vehicle (IDV). The contract is for the aseptic fill and finish manufacturing of succinylcholine chloride injection solution into 10 mL...
- Battelle Memorial Institute was awarded a $5.9 million delivery order on September 29, 2023, to provide testing services supporting the translational development of next-generation botulism therapeutic products for the Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract is a cost-plus-fixed-fee delivery order with an ultimate completion date of April 5, 2027, and carries no set-aside designation. Work will be performed in Columbus, Ohio. ASPR, a component of...
- This is a cost-plus-fixed-fee delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $1,660,449.00 contract is for the characterization of a non-paralyzing botulinum neurotoxin (BoNT)-based biopharmaceutical for the treatment of neuropathic pain. The work will involve conducting nonclinical...
- W911SR22D0009Indefinite Delivery Contract
- W911SR22D0009-W911SR22F0073Delivery Order
The U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense awarded a delivery order valued at $4.86 million to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) on June 16, 2022, with completion targeted for February 28, 2025. This cost-plus-fixed-fee delivery order supports research and development activities focused on developing an FDA-licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure. The work will be performed in Alachua, Florida, and represents part of the government's broader medical countermeasure development strategy for chemical and biological defense applications. No set-aside designation was applied to this award. Resilience Government Services holds a $249 million Indefinite Delivery Contract with the Department of the Army's Acquisition Support Center that serves as the underlying vehicle for this delivery order, positioning the company as a key provider for FDA-approved medical countermeasures supporting chemical and biological defense programs. The contractor, founded in 2020, specializes in biomanufacturing and has demonstrated expertise across the full development lifecycle, from early-stage research through late-stage product development, including process development, clinical trials, and manufacturing scale-up. This delivery order aligns with the company's established track record of advancing monoclonal antibody countermeasures through clinical trials and regulatory approval processes with the Department of Defense and Department of Health and Human Services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00009 | Funding Only Action | ($27k) | 9/12/25 | |
| P00008 | Other Administrative Action | $0 | 6/25/25 | |
| P00006 | Funding Only Action | $0 | 4/10/24 | |
| P00005 | Supplemental Agreement for work within scope | $999.9k | 11/2/23 | |
| P00004 | Other Administrative Action | $1.1m | 8/3/23 |